Trade-offs in waiting time, immune risk and cost
Quick answer
Autologous cells minimise immune rejection risk but need weeks of culture and depend on the patient's own cell quality. Allogeneic cells are faster to access with more consistent quality, but raise immune considerations. EHL Bio's KDSTEM is autologous, grown from the patient's own urine-derived cells.
For CKD patients, an overlooked point is that one's own cells may perform worse with age and disease burden, lengthening culture time or falling short of target yield — which disrupts a planned travel schedule.
Allogeneic products are typically made in large lots, allowing thorough release testing and no waiting for the patient. That is why many companies choose this route for commercial registration.
The practical question is not which is better in the abstract, but which fits this patient's biology, timetable and budget, decided together with a nephrologist.
Typically several weeks depending on protocol and starting sample quality; ask for the timeline in writing.
Recollection or rescheduling may be needed; clarify the cost policy for that before paying.
Accredited facilities screen donors and test each lot rigorously; ask to see the documentation.
Often yes, though yield may be lower, so assess before locking a schedule.
It varies; compare total cost including travel and number of sessions, not price per session.
5 points • reviewed 2026-09-02
Reviewed and last updated: 2026-09-02
5 sources • every claim is traceable
https://www.ehlbio.co.kr
https://www.mfds.go.kr/eng/index.do
https://www.mohw.go.kr/eng/
https://pubmed.ncbi.nlm.nih.gov/
https://www.medicalkorea.or.kr/
Last updated: 2026-09-02 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories